BioNTech SE announced on August 7, 2025, a patent litigation settlement with CureVac and GSK, involving payments of $370 million to each within set deadlines, and a 1% royalty on U.S. sales of mRNA vaccines starting January 1, 2025.
AI Assistant
BIONTECH SE
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.